Sectors
ONCY
Oncolytics Biotech Inc.
0.85
2 x 0.59
2 x 1.09
bid
ask
-
0.01
0.82%
02:09 PM
timesize
| Ytd | -2.34% | |
| 1y | -18.31% |
0.83
day range
0.87
0.73
52 week range
1.51
| Open | 0.86 | Prev Close | 0.86 | Low | 0.83 | High | 0.87 | Mkt Cap | 108.33M |
| Vol | 310.39K | Avg Vol | 1.27M | EPS | -0.35 | P/E | N/A | Forward P/E | -3.02 |
| Beta | 1.13 | Short Ratio | 3.51 | Inst. Own | 1.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-16 | 50-d Avg | 0.85 | 200-d Avg | 0.94 | 1yr Est | 4.85 |
| Income Statement | |||
| Operating Expenses | 9.38M | ||
| Research and Development Expense | 4.26M | ||
| Selling, General and Administrative Expense | 5.12M | ||
| Operating Income | -9.38M | ||
| Income Tax Expense | 101.00K | ||
| Net Income | -9.44M | ||
| Net Income Common Stock | -9.44M | ||
| Net Income Common Stock (USD) | -9.44M | ||
| Consolidated Income | -9.44M | ||
| Earnings per Basic Share | -0.08 | ||
| Earnings per Basic Share (USD) | -0.08 | ||
| Earnings per Diluted Share | -0.08 | ||
| Earning Before Interest & Taxes (EBIT) | -9.34M | ||
| Earning Before Interest & Taxes (USD) | -9.34M | ||
| Weighted Average Shares | 119.74M | ||
| Weighted Average Shares Diluted | 119.74M | ||
| Balance Sheet | |||
| Cash and Equivalents | 4.12M | ||
| Cash and Equivalents (USD) | 4.12M | ||
| Trade and Non-Trade Receivables | 1.21M | ||
| Current Assets | 7.07M | ||
| Property, Plant & Equipment Net | 602.00K | ||
| Total Assets | 7.67M | ||
| Debt Current | 138.00K | ||
| Total Debt | 448.00K | ||
| Current Liabilities | 5.23M | ||
| Debt Non-Current | 310.00K | ||
| Total Liabilities | 13.84M | ||
| Accumulated Retained Earnings (Deficit) | -448.18M | ||
| Accumulated Other Comprehensive Income | 6.23M | ||
| Shareholders Equity | -6.17M | ||
| Shareholders Equity (USD) | -6.17M | ||
| Assets Non-Current | 602.00K | ||
| Total Debt (USD) | 448.00K | ||
| Liabilities Non-Current | 8.61M | ||
| Trade and Non-Trade Payables | 3.41M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 86.00K | ||
| Net Cash Flow from Financing | 6.77M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -1.38M | ||
| Issuance (Purchase) of Equity Shares | 6.77M | ||
| Net Cash Flow from Operations | -8.14M | ||
| Effect of Exchange Rate Changes on Cash | -11.00K | ||
| Share Based Compensation | 1.79M | ||